Global Epistaxis Market Is Expanding Owing To Rising Air Pollution And Increasing Demand For Functional Endoscopic Sinus Surgeries

 

Epistaxis Market

Overview:

Epistaxis is a term used to describe bleeding from the nose. There are two types of nose bleed: anterior and posterior. Anterior epistaxis occurs when bleeding originates in the anterior nasal cavity, usually from the Kiesselbach plexus on the nasal septum. Posterior epistaxis is a more serious condition and usually involves both nostrils. The etiology of Epistaxis can be complex and multifactorial. Medications can also trigger epistaxis. These include aspirin, clopidogrel, nonsteroidal anti-inflammatory drugs, and warfarin. A nosebleed is the loss of blood from the lining inside the nose. The bleed is usually minor and isn't dangerous, it can lead to feeling dizzy, fainting, or losing balance. Nose bleeds are very common, especially in children and older people. Most people with nose bleeds stop it on their own, whereas some may need medical treatment.

Market Dynamics:

Increasing partnerships are estimated to augment growth of the global Epistaxis Market over the forecast period. For instance, a private equity fund Argonaut Private Equity and a leading provider of concrete construction materials FABco, entered in a partnership in September 2021. With this new partnership they are planning to reinforce growth in every segment. Moreover, lack of skilled labor is anticipated to restrain growth of the global epistaxis market over the forecast period.

Impact of COVID-19:

The pandemic affected many nations and it was declared as a public health emergency by the World Health Organization in 2020. Several countries imposed strict restriction to avoid further transmission of the virus. The global economy was ruptured owing to halting of several trade activities and shutting down of several businesses across the globe. The pandemic had a major impact on the healthcare sector. The number of patients was increasing on a daily basis and it caused huge stress on the healthcare system. There was a shortage of drugs, medical equipment and skilled professional’s across the world. COVID-19 affects the respiratory system and the nasal secretions, otolaryngologists were concerned about managing epistaxis in COVID-19 patients. This had a negative impact on the growth of the global Epistaxis Market.

Key Takeaways:

 

The global Epistaxis Market size is estimated to be valued at US$ 145.9 million in 2019 and is expected to witness a CAGR of 5.4% over the forecast period (2019–2027). For instance, Intersect ENT and Medtronic, signed a binding agreement in August 2021. As per the agreement Medtronic will buy all outstanding shares of Intersect ENT for USD 1.1 billion.

North America is anticipated to witness significant growth in the global epistaxis market over the forecast period, owing to growing prevalence blood disorders, nasal and paranasal sinus cancers.

Major players operating in the global Epistaxis Market are Smith & Nephew, Novartis AG, Bayer, Noramco, F. ASCHER & CO., INC., Johnson & Johnson Health Care Systems Inc., Elanor Surgicals, Teva Pharmaceuticals USA, Sterimed Group, Camber Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Amneal Pharmaceuticals LLC, Angiplast, Amneal Pharmaceuticals LLC, Pfizer Inc., Lannett, AdvaCare Pharma, Takeda Pharmaceutical Company Limited, Aurobindo Pharma USA, Zydus Cadila,  and Par Pharmaceutical.